drugset / Trial / NCT02489760

Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study

NCT02489760

Phase 4 Unknown 30 enrolled Chung Shan Medical University
RandomizedCrossoverOpen-labelTreatment

Summary

To determine the safety and efficacy of switch effects to adalimumab in etanercept-treated AS patients.

Timeline

Start
2008-07
Primary completion
2015-12
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg Subcutaneous
Subject Etanercept Protein / enzyme biologic 25 mg Subcutaneous
Subject Etanercept Protein / enzyme biologic 50 mg Subcutaneous